Introduction

53
Triple negative breast cancer, which lacks estrogen and progesterone receptors and is 54 negative for human epidermal growth factor receptor 2 (HER-2), is highly aggressive form of and has a potential to treat breast cancer. One of such compounds is metformin.
67
Metformin is the most commonly used oral drug to treat type 2 diabetes and has 68 potential anti-cancer effects in patients with breast cancer [13] [14] [15] 
Statistical analysis
192
Statistical analysis was performed with GraphPad Prism (v6; GraphPad Software, Inc., La
193
Jolla, CA, USA) using one-way ANOVA or two-way ANOVA, followed by Bonferroni,
194
Tukey or Sidak test. Statistically significant results are displayed as follows: *P≤0.05; 195 **P≤0.01, *** P≤ 0.001.
196
Results
197
The effect of nutrient availability on proliferation of MDA-MB- of MDA-MB-231 cells in RPMI-1640 medium without glucose ( Fig. 2A, B) . serum, but without glutamine, glucose and pyruvate (Fig. 2C, D) . Serum-free RPMI-1640 glucose, glutamine and pyruvate (Fig. 3D, F) . alanine, glycine, glutamate, proline, serine, asparagine and aspartate (Table 1) .
315
Tumour spheroids were grown in complete DMEM or MEM and treated with 5 mM 316 metformin for 72 hours. Cell survival was determined by propidium iodide and calcein 317 staining (Fig. 4) . Untreated spheroids had similar size independent from cell culture medium.
318
Metformin disintegrated tumour spheroids grown in MEM but not in DMEM (Fig. 4A, B) .
319
Cell survival was lower in untreated tumour spheroids grown in MEM than in DMEM.
320
Metformin did not further reduce cell survival in tumour spheroids grown in MEM or DMEM
321
( Fig. 4C) . in DMEM without glucose and pyruvate (Fig. 5A, B) . Metformin increased phosphorylation 341 of ACC in the absence of pyruvate, glucose and their combination (Fig. 5A, C) . Deficiency of 342 glutamine did not enhance metformin-stimulated AMPK or ACC phosphorylation. in MEM without pyruvate to about 60% (Fig. 6C ), but it did not have any direct effect on 378 their survival (<4% propidium iodide positive MDA-MB-231 cells) (Fig. 6D) . 
